Inland Empire Liver Foundation

Recent papers from Inland Empire Liver Foundation

1. A randomised, double‐blind, placebo‐controlled study of the LAG‐3‐depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitisAlimentary Pharmacology & Therapeutics · 2023
2. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialJournal of Hepatology · 2022
3. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging studyJournal of Hepatology · 2021
4. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II studyJournal of Hepatology · 2020
5. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialHepatology · 2020
6. Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical PracticeThe American Journal of Gastroenterology · 2019
7. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and ThrombocytopeniaGastroenterology · 2018
8. Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir ( FOUR ward study)Liver International · 2016
9. Structural and Electronic Properties of Graphdiyne Carbon Nanotubes from Large-Scale DFT CalculationsThe Journal of Physical Chemistry C · 2016